Aprepitant for Postoperative Nausea and Vomiting in Laparoscopic Hysterectomy

Gachon University Gil Medical Center

Status: Completed

Conditions: Postoperative Nausea and Vomiting

Treatments: Drug: Aprepitant

Study type: Interventional

Funder types: Other

Identifiers

NCT01440673

GIRBA2085

Details and patient eligibility

About

• Gynecological surgery is associated with a high incidence of postoperative nausea and vomiting.
• NK1 receptor antagonists such as aprepitant appear to be highly effective for treating acute and delayed emesis, and yet understanding of the efficacy of different doses of aprepitant is limited.
• We performed a prospective, randomized, double-blinded placebo-controlled study of 123 female adults scheduled for laparoscopic hysterectomy who received 80 mg aprepitant, 125 mg aprepitant, or a placebo.

Full description

123 female patients (ages 21-60) undergoing laparoscopic hysterectomy

1. 80mg aprepitant
2. 125mg aprepitant
3. placebo

Incidences of nausea, vomiting/retching, and use of rescue antiemetics were recorded at 0, 1, 2, 24, and 48 h after surgery.

Enrollment: 150 patients

Sex: Female

Ages: 21 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• female laparoscopic hysterectomy isoflurane anesthesia postoperative opioid use

Exclusion criteria

• liver disease neurologic disease active pulmonary disease cardiac arrhythmia allergies to any perioperative medications

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

150 participants in 2 patient groups

aprepitant 125mg

Active Comparator group

Description:

NK1 receptor antagonist

Treatment:

Drug: Aprepitant

Aprepitant 80 mg

Active Comparator group

Treatment:

Drug: Aprepitant